Effect of Rofacoxib, a highly selective cyclooxygenase-2 inhibitor, on portal pressure in cirrhotic rats
- VernacularTitle:选择性环氧合酶-2抑制剂对肝硬化大鼠门脉压力的影响
- Author:
Chuantao TU
;
Jinsheng GUO
;
Jiyao WANG
;
- Publication Type:Journal Article
- Keywords:
Cyclooxygenase 2;
Cyclooxygenase 2 inhibitor;
Cirrhosis;
Portal hypertension
- From:
Chinese Journal of Digestion
2001;0(07):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the role of cyclooxygenase 2 (COX 2) in the forming of portal hypertension and whether a selective COX 2 inhibitor can reduce the portal hypertension or not. Methods Cirrhotic Sprague Dawley rat was induced by carbon tetrachloride (CCl 4) intraperitoneally for 8 weeks. The animals were divided into three groups: 10 normal rats served as control group; the other 15 rats, which received CCl 4 intraperitoneally twice a week and rofecoxib (10 mg/kg) by gavages daily, served as treatment group; another 15 rats, which were induced cirrhosis by CCl 4 but given placebo (saline solution ) instead of rofecoxib, served as placebo group. After 8 weeks of CCl 4 induction, portal pressure was measured, and the levels of thromboxane B 2 (TXB 2), and prostaglandin (PG)E 2 in the liver tissues were determined by enzyme immunoassay. Furthermore, liver histopathological analysis was performed in H E and Masson's trichrome staining sections. Results Portal pressure in the rats of rofecoxib group was significantly decreased compared to that in the placebo group [(11.95?1.05) mm Hg vs. (13.45?1.15) mm Hg; P
